Repair and regeneration of ocular tissue using postpartum-derived cells

Patent metadata

Field	Value
Publication number	US-9234172-B2
Application number	US-201414444689-A
Country	US
Kind code	B2
Filing date	Jul 28, 2014
Priority date	Jun 27, 2003
Publication date	Jan 12, 2016
Grant date	Jan 12, 2016

Abstract

Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.

First claim

What is claimed is:

1. A method of inducing differentiation of neural progenitor cells comprising co-culturing neural progenitor cells with isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, wherein the co-culturing induces the differentiation of the neural progenitor cells, and wherein the isolated umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

2. The method of claim 1 , wherein the neural progenitor cells differentiate into mature neurons, astrocytes or mature oligodendrocytes.

3. The method of claim 2 , wherein the differentiated cells are positive for TuJ1, GFAP, or MBP.

4. The method of claim 1 , wherein the differentiated cells lack expression of nestin.

5. The method of claim 1 , wherein trophic factors secreted by the isolated umbilicus-derived cells induce differentiation.

6. The method of claim 1 , wherein the isolated umbilicus-derived cells further have the following characteristics:
a) potential for at least 40 population doublings in culture;
b) production of CD10, CD13, CD44, CD73, and CD90;
c) lack of production of CD31, CD34, CD45, and CD141, and
d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

7. The method of claim 6 , wherein the isolated umbilicus-cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.

8. A method of increasing yield of differentiated neural progenitor cells comprising co-culturing neural progenitor cells with isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, wherein the co-culturing increases the yield of the differentiated neural progenitor cells, and wherein the isolated umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

9. The method of claim 8 , wherein the differentiated cells are mature neurons, astrocytes or mature oligodendrocytes.

10. The method of claim 9 , wherein the differentiated cells are positive for TuJ1, GFAP, or MBP.

11. The method of claim 9 , wherein the differentiated cells lack expression of nestin.

12. The method of claim 8 , wherein the isolated umbilicus-derived cells further have the following characteristics:
a) potential for at least 40 population doublings in culture;
b) production of CD10, CD13, CD44, CD73, and CD90;
c) lack of production of CD31, CD34, CD45, and CD141, and
d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

13. The method of claim 9 , wherein the isolated umbilicus-derived cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.

14. A method of inducing differentiation of neural progenitor cells comprising contacting neural progenitor cells with isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, wherein the contacting induces the differentiation of the neural progenitor cells, and wherein the isolated umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

15. The method of claim 14 , wherein the neural progenitor cells differentiate into mature neurons, astrocytes or mature oligodendrocytes.

16. The method of claim 14 , wherein the differentiated cells are positive for TuJ1, GFAP, or MBP.

17. The method of claim 14 , wherein the differentiated cells lack expression of nestin.

18. A method of increasing yield of differentiated neural progenitor cells comprising contacting neural progenitor cells with isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, wherein the contacting increases the yield of the differentiated neural progenitor cells, and wherein the isolated umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.

19. The method of claim 18 , wherein the differentiated cells are mature neurons, astrocytes or mature oligodendrocytes.

20. The method of claim 18 , wherein the differentiated cells are positive for TuJ1, GFAP, or MBP.

21. The method of claim 18 , wherein the differentiated cells lack expression of nestin.

Assignees

• Depuy Synthes Products Llc
• Depuy Synthes Products Inc

Inventors

• Mistry Sanjay
• Messina Darin

Classifications

• C12N2500/34

  Sugars · CPC title

• C12N2506/02

  from embryonic cells · CPC title

• C12N5/0605 Primary

  Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly · CPC title

• C12N2502/02

  embryonic cells · CPC title

• C12N2501/21

  Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4 · CPC title